Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lucentis Approved for AMD | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Lucentis Approved for AMD

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genentech has received FDA approval of Lucentis for the treatment of neovascular (wet) age-related macular degeneration (AMD). The FDA approved Lucentis after a six-month Priority Review and will ship the product immediately.

The Phase III trials showed that 95% of patients treated with Lucentis maintained their vision and vision improved by at least three lines (or 15 letters) on the study eye chart in as many as 40% of these patients at one year. Lucentis is an injectable bio-drug designed to inhibit the formation and leakage of new blood vessels in the back of the eye, the primary cause of central vision loss associated with this disease.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters